PURPOSE: This study assessed the presentation and institutional outcomes treating brain metastases (BM) of breast cancer (BC), non-small cell lung cancer (NSCLC), and melanoma origin. METHODS: Patients with brain metastases treated between 2014 and 2019 with primary melanoma, NSCLC, and BC were identified. Overall survival (OS) was calculated from dates of initial BM diagnosis using the Kaplan-Meier method. RESULTS: A total of 959 patients were identified including melanoma (31%), NSCLC (51%), and BC (18%). Patients with BC were younger at BM diagnosis (median age: 57) than NSCLC (65) and melanoma patients (62, p < 0.0001). Breast cancer patients were more likely to present with at least 5 BM (27%) than NSCLC (14%) and melanoma (13%), leptomeningeal disease (23%, 6%, and 6%, p = 0.0004) and receive whole brain radiation therapy (WBRT) (58%, 37%, and 22%, p < 0.0001). There were no differences in surgical resection (24%, 24%, and 29%, p = 0.166). Median OS was shorter for BC patients (9.9, 10.3, and 13.7 months, p = 0.0006). CONCLUSION: Breast cancer patients were more likely to be younger, present with advanced disease, require WBRT, and have poorer OS than NSCLC and melanoma patients. Further investigation is needed to determine which BC patients are at sufficient risk for brain MRI screening.
PURPOSE: This study assessed the presentation and institutional outcomes treating brain metastases (BM) of breast cancer (BC), non-small cell lung cancer (NSCLC), and melanoma origin. METHODS: Patients with brain metastases treated between 2014 and 2019 with primary melanoma, NSCLC, and BC were identified. Overall survival (OS) was calculated from dates of initial BM diagnosis using the Kaplan-Meier method. RESULTS: A total of 959 patients were identified including melanoma (31%), NSCLC (51%), and BC (18%). Patients with BC were younger at BM diagnosis (median age: 57) than NSCLC (65) and melanoma patients (62, p < 0.0001). Breast cancer patients were more likely to present with at least 5 BM (27%) than NSCLC (14%) and melanoma (13%), leptomeningeal disease (23%, 6%, and 6%, p = 0.0004) and receive whole brain radiation therapy (WBRT) (58%, 37%, and 22%, p < 0.0001). There were no differences in surgical resection (24%, 24%, and 29%, p = 0.166). Median OS was shorter for BC patients (9.9, 10.3, and 13.7 months, p = 0.0006). CONCLUSION: Breast cancer patients were more likely to be younger, present with advanced disease, require WBRT, and have poorer OS than NSCLC and melanoma patients. Further investigation is needed to determine which BC patients are at sufficient risk for brain MRI screening.
Authors: Daniel N Cagney; Allison M Martin; Paul J Catalano; Paul D Brown; Brian M Alexander; Nancy U Lin; Ayal A Aizer Journal: JAMA Oncol Date: 2018-07-01 Impact factor: 31.777
Authors: Paul M Jeene; Kim C de Vries; Johanna G H van Nes; Johannes J M Kwakman; Gerda Wester; Tom Rozema; Pètra M Braam; Jaap D Zindler; Peter Koper; Joost J Nuyttens; Hanneke A Vos-Westerman; Ilona Schmeets; Charles G H J Niël; Stefan Hutschemaekers; Yvette M van der Linden; Joost J C Verhoeff; Lukas J A Stalpers Journal: Acta Oncol Date: 2017-12-23 Impact factor: 4.089
Authors: Sarah B Goldberg; Kurt A Schalper; Scott N Gettinger; Amit Mahajan; Roy S Herbst; Anne C Chiang; Rogerio Lilenbaum; Frederick H Wilson; Sacit Bulent Omay; James B Yu; Lucia Jilaveanu; Thuy Tran; Kira Pavlik; Elin Rowen; Heather Gerrish; Annette Komlo; Richa Gupta; Hailey Wyatt; Matthew Ribeiro; Yuval Kluger; Geyu Zhou; Wei Wei; Veronica L Chiang; Harriet M Kluger Journal: Lancet Oncol Date: 2020-04-03 Impact factor: 41.316
Authors: Nicholas B Figura; Victoria T Rizk; Avan J Armaghani; John A Arrington; Arnold B Etame; Hyo S Han; Brian J Czerniecki; Peter A Forsyth; Kamran A Ahmed Journal: Breast Cancer Res Treat Date: 2019-06-17 Impact factor: 4.872
Authors: Michael A Davies; Philippe Saiag; Caroline Robert; Jean-Jacques Grob; Keith T Flaherty; Ana Arance; Vanna Chiarion-Sileni; Luc Thomas; Thierry Lesimple; Laurent Mortier; Stergios J Moschos; David Hogg; Iván Márquez-Rodas; Michele Del Vecchio; Céleste Lebbé; Nicolas Meyer; Ying Zhang; Yingjie Huang; Bijoyesh Mookerjee; Georgina V Long Journal: Lancet Oncol Date: 2017-06-04 Impact factor: 41.316
Authors: Douglas Kondziolka; Hideyuki Kano; Gillian L Harrison; Huai-Che Yang; Donald N Liew; Ajay Niranjan; Adam M Brufsky; John C Flickinger; L Dade Lunsford Journal: J Neurosurg Date: 2010-10-01 Impact factor: 5.115
Authors: Ryan T Hughes; Adrianna H Masters; Emory R McTyre; Michael K Farris; Caroline Chung; Brandi R Page; Lawrence R Kleinberg; Jaroslaw Hepel; Joseph N Contessa; Veronica Chiang; Jimmy Ruiz; Kounosuke Watabe; Jing Su; John B Fiveash; Steve Braunstein; Samuel Chao; Albert Attia; Diandra N Ayala-Peacock; Michael D Chan Journal: Int J Radiat Oncol Biol Phys Date: 2019-04-06 Impact factor: 7.038
Authors: Eric L Chang; Jeffrey S Wefel; Kenneth R Hess; Pamela K Allen; Frederick F Lang; David G Kornguth; Rebecca B Arbuckle; J Michael Swint; Almon S Shiu; Moshe H Maor; Christina A Meyers Journal: Lancet Oncol Date: 2009-10-02 Impact factor: 41.316
Authors: Nancy U Lin; Virginia Borges; Carey Anders; Rashmi K Murthy; Elisavet Paplomata; Erika Hamilton; Sara Hurvitz; Sherene Loi; Alicia Okines; Vandana Abramson; Philippe L Bedard; Mafalda Oliveira; Volkmar Mueller; Amelia Zelnak; Michael P DiGiovanna; Thomas Bachelot; A Jo Chien; Ruth O'Regan; Andrew Wardley; Alison Conlin; David Cameron; Lisa Carey; Giuseppe Curigliano; Karen Gelmon; Sibylle Loibl; JoAl Mayor; Suzanne McGoldrick; Xuebei An; Eric P Winer Journal: J Clin Oncol Date: 2020-05-29 Impact factor: 44.544